Online inquiry

IVTScrip™ pSP6-VEE-mRNA-Anti-LRRC15, ABBV-085 Vector   (CAT#: GTVCR-WQ145MR)

This product GTVCR-WQ145MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the SP6 promoter to efficiently generate mRNA ecoding antibody which targeting LRRC15. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter SP6
Resistance Ampicillin
Species Chimeric; Humanized
RefSeq NM_001135057.3
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 131578
UniProt ID Q8TF66
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pSP6-VEE-mRNA-Anti-LRRC15, ABBV-085 Vector (GTVCR-WQ145MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ2614MR IVTScrip™ pSP6-VEE-mRNA-Anti-TNFRSF13C, VAY-736 Vector Vector VAY-736
GTVCR-WQ2128MR IVTScrip™ pT7-VEE-mRNA-Anti-DLL4&VEGFA, OMP-305B83 Vector Vector OMP-305B83
GTVCR-WQ2217MR IVTScrip™ pSP6-VEE-mRNA-Anti-PCSK9, PF-05335810 Vector Vector PF-05335810
GTVCR-WQ2024MR IVTScrip™ pT7-VEE-mRNA-Anti-CD38, MOR-03087 Vector Vector MOR-03087
GTVCR-WQ470MR IVTScrip™ pSP6-VEE-mRNA-Anti-TNFSF11, AMG162 Vector Vector AMG162
GTVCR-WQ1368MR IVTScrip™ pT7-VEE-mRNA-Anti-TNFRSF1A, HL036337 Vector Vector HL036337
GTVCR-WQ833MR IVTScrip™ pSP6-VEE-mRNA-Anti-GP, c13C6-FR1-N Vector Vector c13C6-FR1-N
GTVCR-WQ2103MR IVTScrip™ pT7-VEE-mRNA-Anti-Felcat NGF, NV-02 Vector Vector NV-02
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW